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ABSTRACT
Tuberculosis (TB) is the major opportunistic infection of HIV-1-infected patients in developing countries. Con-
current infection with TB results in immune cells having enhanced susceptibility to HIV-1 infection, which
facilitates entry and replication of the virus. Cumulative data from earlier studies indicate that TB provides
a milieu of continuous cellular activation and irregularities in cytokine and chemokine circuits that favor vi-
ral replication and disease progression. To better understand the interaction of the host with HIV-1 during
active tuberculosis, we investigated in vivo expression of the HIV-1 coreceptors, CCR5 and CXCR4, and cir-
culating levels of the inhibitory -chemokines, macrophage inflammatory protein-1- (MIP-1), macrophage
inflammatory protein-1- (MIP-1), and regulated upon activation T cell expressed and secreted (RANTES),
in HIV-positive individuals with and without active pulmonary tuberculosis. We found a significant decrease
from normal in the fraction of CD4 T cells expressing CCR5 and CXCR4 in individuals infected with HIV.
However, CCR5 and CXCR4 expression did not differ significantly between HIV patients with and without
tuberculosis. Higher amounts of MIP-1, MIP-1, and RANTES were detected in plasma of HIV-1-positive




ANUMBER OF INFECTIOUS DISEASES often encountered duringthe course of human immunodeficiency virus (HIV) infec-
tion have been reported to enhance HIV-1 replication and dis-
ease progression.1–5 Tuberculosis (TB) is one of the most im-
portant cofactors accelerating HIV disease progression toward
acquired immunodeficiency syndrome (AIDS).6 The mecha-
nisms by which TB leads to augmentation of HIV-1 load and
activity are not fully understood. A number of different mech-
anisms have been proposed to explain this phenomenon. These
include augmentation in production of proinflammatory cyto-
kines [tumor necrosis factor- (TNF-) and interleukin-6 (IL-
6)] in the course of TB to generate a microenvironment en-
hancing the productive infection of local lymphocytes by HIV,7
the constitutive degradation of IB-, the major cytoplasmic in-
hibitor of nuclear factor B (NF-B), in freshly isolated pe-
ripheral blood mononuclear cells (PBMC) and monocytes from
patients with TB,8 activation of mitogen-activated protein
(MAP) kinase pathways,9 and dysregulations in -chemokines10
and their receptors.11
Chemokines are potent leukocyte activators and chemoat-
tractants. Macrophage inflammatory protein-1 (MIP-1),
MIP-1, and regulated upon activation normal T cell expressed
and secreted (RANTES) are the major -chemokines produced
in response to Mycobacterium tuberculosis infection.12
Chemokines are the natural ligands for chemokine receptors,
CCR5 and CXCR4, which can also act as HIV coreceptors. M-
tropic HIV-1 isolates use CCR5 as coreceptor early in the course
of HIV infection, whereas T cell tropic viruses use CXCR4 for
entry into CD4 T cells, typically in a later stage of infection.
In vitro studies have demonstrated that -chemokines inhibit
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HIV-1 by blocking the C–C chemokine receptor-5 (CCR5),
which has been identified as a necessary coreceptor for M-tropic
strains of HIV-1.13 However, the role of -chemokines in HIV-
1 disease progression in vivo remains unclear.
Infection with M. tuberculosis is endemic in India and TB
is the most common opportunistic infection in HIV-1–seropos-
itive individuals in this country. Therefore, we felt it is impor-
tant to determine the effects mediated by M. tuberculosis in-
fection on profiles of -chemokines and their receptors in
HIV-1-infected individuals, and explore whether their dysreg-
ulation is associated with the higher HIV-1 activity seen in HIV
patients with concurrent tuberculosis.
MATERIALS AND METHODS
Study population
The study population was composed of 28 HIV-seropositive
patients recruited from the HIV/TB Clinics of the Tuberculo-
sis Research Centre and the Government Hospital for Thoracic
Medicine, Chennai, India. Half of these individuals (14) also
had active pulmonary TB, while the other half (14) had no ev-
idence of lung disease based on physical and chest radiologi-
cal examination. A group of 10 HIV-seronegative patients with
active pulmonary TB was also included in the study. The con-
trol group consisted of 10 healthy volunteers. Each group was
composed of equal numbers of men and women, with ages rang-
ing from 23 to 57 years. The study were approved by the In-
stitutional Research and Ethics Committees of the Tuberculo-
sis Research Centre and written informed consent was obtained
from all subjects before enrollment.
The diagnosis of tuberculosis was based on sputum smear
examination for acid-fast bacilli and confirmed by culture for
M. tuberculosis. HIV was diagnosed using two rapid tests (HIV
Tridot, J. Mitra, India; CombAids, Span Diagnostics, India),
and a positive result was confirmed by a third test (Western
blot, J. Mitra, India). None of the patients were receiving anti-
tuberculosis or antiretroviral treatment at the time of intake into
the study. Of venous blood 10 ml was collected in EDTA-coated
vacutainers (Becton Dickinson) from each of the study subjects.
Hemoglobin levels as well as total and differential white blood
cell counts were determined for all samples using an automated
hematology analyzer (ABX, France).
Phenotypic analysis of cell populations
Surface expression of CCR5 and CXCR4 on mononuclear
cells in whole blood was assessed by immunostaining and flow
cytometry. In brief, 100 l of whole blood was incubated with
combinations of monoclonal antibodies against CD3, CD4,
CCR5, and CXCR4, at 4°C for 30 min. Mouse isotype IgG1
and IgG2 antibodies were used as control for nonspecific stain-
ing. All antibodies were conjugated with either fluorescein
isothiocyanate (FITC) or phycoerythrin (PE) and purchased
from Becton Dickinson (Mountain View, CA). Red blood cells
were lysed using 1 RBC lysis buffer. Cells were washed
twice in ice-cold phosphate-buffered saline (PBS) and fixed in
500 l of 1% paraformaldehyde for flow cytometric analysis.
Samples were acquired using a FACSort flow cytometer (Bec-
ton Dickinson) and data were analyzed employing the Cell
Quest software. A minimum of 10,000 lymphocytes was used
for analysis.
Measurement of chemokines
Plasma levels of MIP-1, MIP-1, and RANTES were quan-
titated by ELISA using commercially available kits (Biosource
immunoassay kit, Biosource International, Belgium), following
the manufacturer’s protocol. The detection limits of the assays
were 6 pg/ml for MIP-1, 15.6 pg/ml for MIP-1, and 31.5
pg/ml for RANTES.
Statistical analysis
Data are presented as mean  SEM (standard error of mean).
Comparison between groups was performed using the
Mann–Whitney U test and correlations were made by using the
Spearman’s test. A value of p  0.05 was considered statisti-
cally significant. The Statistical Package for Social Sciences,
version 8.0 (SPSS Inc, Chicago, IL) was used for all statistical
analysis.
RESULTS
Expression of HIV coreceptors on PBMC
To investigate the influence of active TB on HIV corecep-
tor expression in HIV patients, we determined expression of
CCR5 and CXCR4 in HIV patients with and without TB, and
compared them with HIV-negative TB patients and healthy con-
trols (Table 1). The percentages and absolute numbers of cir-
culating T (CD3) cells and helper (CD4) T cells in HIV-neg-
ative TB patients did not differ from those in healthy controls.
The mean CD3 and CD4 T cell count in HIV negative TB
patients was 1315  84 and 525  37, respectively. Healthy
controls had a mean CD3 and CD4 T cell count of 1385 
62 and 687  45, respectively. However, percentages and num-
bers of CD3 and CD4 T cells were significantly decreased
in the HIV-positive groups as compared to the HIV-negative
groups, irrespective of the presence or absence of tuberculosis.
The mean CD3 and CD4 T cell count in individuals with
HIV alone was 702  25 and 143  12, respectively. Those
with both HIV and TB had mean CD3 and CD4 T cell counts
of 726  31 and 151  15, respectively.
Since mean fluorescence intensity (MFI) is believed to be a
better parameter than percent positive cells for the analysis of
cells that give a continuum of fluorescence intensity, we also
analyzed our data using MFI and found very good correlation
between MFI and percent positive cells. We have therefore rep-
resented our data as percent positive cells. Greater proportions
of T cells expressed CXCR4 as opposed to CCR5. For exam-
ple, 37.8% of CD3 leukocytes expressed CXCR4, whereas
only 29.2% of these cells expressed CCR5. Also, CXCR4 was
expressed on a greater percentage of CD4 cells (18.2%) than
CCR5 (6.7%).
Expression of CCR5 was significantly reduced from normal
on total T (CD3) cells of persons with HIV-1, with pulmonary
TB, and those with both infections (29.2  4.5 vs. 11.3  2.9,
15.6  1.4, and 12.1  2.7, respectively) (p  0.05). When the
CD4 subsets of T cells were analyzed, no significant differ-
ence could be observed in CCR5 expression between TB pa-
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tients and healthy donors. On the other hand, a significant de-
crease was observed in the fraction of CD4 T cells express-
ing CCR5 in the HIV-positive groups (1.6  0.5 and 2.5  0.8)
as compared to the HIV-negative groups (8.1  2.5 and 6.7 
1.4) (p  0.05). However, no difference was found in the pro-
portion of CD3 and CD4 T cells expressing CCR5 between
HIV patients with and without tuberculosis.
CXCR4 expression on total T (CD3) cells did not differ
significantly based on disease groupings. However, analysis of
the CD4 subset of T cells revealed that CXCR4 expression
was significantly decreased in the HIV-positive groups (5.7 
1.2 and 9.6  2.6) when compared to the HIV-negative groups
(13.6  2.1 and 18.2  3.0) (p  0.05). Between the two HIV-
positive groups, the one composed of individuals with concur-
rent tuberculosis had a smaller proportion of CD4 T cells ex-
pressing CXCR4 as compared to the TB negative group.
Though the decrease was about 2-fold, the difference was not
found to be statistically significant.
Production of chemokines in HIV and TB
To assess whether the -chemokine profile is specific to
HIV-positive TB patients, or common to HIV in the absence of
tuberculosis infection, we measured three -chemokines, MIP-
1, MIP-1, and RANTES, in HIV patients with and without
active TB, and compared them with appropriate controls (Table
2). While individuals with either HIV or TB had plasma levels
of MIP-1 similar to those of healthy controls, patients with
both infections had elevated MIP-1 levels. Increased plasma
levels of MIP-1 were observed in both HIV and TB patients
when compared to healthy controls. Interestingly, very high lev-
els of plasma MIP-1 were detected in HIV-negative TB pa-
tients (82.8  42.4 pg/ml). A comparable amount of RANTES
was detected in the plasma of patients with either infection
alone. On the other hand, those dually infected with HIV and
TB had elevated levels of circulating RANTES. Though the in-
crease in circulating MIP-1, MIP-1, and RANTES levels in
the dually infected group was not statistically significant in
comparison with controls, a trend toward increased production
of these chemokines was obvious in HIV patients with active
TB, indicating that HIV and Mycobacterium tuberculosis may
have an additive effect on -chemokine production. No other
correlations were found between chemokine concentrations.
Correlation of HIV coreceptor expression and
chemokines production
We analyzed the relationship between chemokine production
and chemokine receptor expression in CD4 cell count-
matched (200 cell/l) groups of HIV-positive TB patients and
HIV patients without TB. No significant correlation could be
demonstrated between the two groups.
DISCUSSION
The importance of the copathogenesis of HIV and TB as an
area of intense investigation hinges on the enormity of these in-
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TABLE 1. CCR5 AND CXCR4 EXPRESSION ON CD3 AND CD4 CELLS IN THE STUDY GROUPSa
HIVTBb HIVTBc HIVTBd HIVTBe
Cell type (n  14) (n  14) (n  10) (n  10)
CCR5 CD3 cells 11.3  2.9f 12.1  2.7f 15.6  1.4f 29.2  4.5
CCR5 CD4 cells 1.6  0.5f 2.5  0.8f 8.1  2.5 6.7  1.4
CXCR4 CD3 cells 30.9  7.4 36.5  5.7 24.6  4.4 37.8  5.5
CXCR4 CD4 cells 5.7  1.2f 9.6  2.6f 13.6  2.1 18.2  3.0
aExpressed as mean percent positive cells  SEM.
bHIVTB, HIV-positive patients with active tuberculosis.
cHIVTB, HIV-positive individuals without active tuberculosis.
dHIVTB, HIV-negative TB patients.
eHIVTB, healthy controls.
fp  0.05 compared to HIVTB.
TABLE 2. PLASMA CHEMOKINE LEVELS IN THE STUDY GROUPSa
HIVTBb HIVTBc HIVTBd HIVTBe
Chemokine (n  14) (n  14) (n  10) (n  10)
MIP-1 5.6  1.5 4.0  1.6 2.6  0.7 2.4  1.0
MIP-1 52.9  16.6 43.1  8.4 82.8  42.4 20.6  0.1
RANTES 2274.4  434.1 1558.7  254.1 1767.1  376.1 1616.5  486.2
aExpressed as pg/ml  SEM.
bHIVTB, HIV-positive patients with active tuberculosis.
cHIVTB, HIV-positive individuals without active tuberculosis.
dHIVTB, HIV-negative TB patients.
eHIVTB, healthy controls.
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tertwined pandemics for world health, and the bidirectional in-
teraction between these two pathogens. HIV and M. tuberculo-
sis not only cocirculate throughout the developing world, but
each has contributed to prevalence and mortality caused by the
other. On one hand, HIV-1 infection predisposes to the devel-
opment of active TB, and, on the other hand, the course of HIV-
related immunodeficiency is worsened by active M. tuberculo-
sis infection.14,15
M. tuberculosis infection in HIV-1-infected individuals en-
hances both systemic3 and local16 viral replication, as well as
HIV transmission to T cells.17 Both relative risk of death and
rates of development of new opportunistic infections are in-
creased in HIV/TB coinfection, compared with CD4 cell-
matched HIV-1-infected subjects without TB.18 In vivo studies
have shown that active TB increases plasma HIV levels, which
decreases once anti-TB treatment is initiated.3 Furthermore,
HIV patients with active TB show evidence of immune activa-
tion, including elevated levels of proinflammatory cyto-
kines.19,20 These combined data suggest that M. tuberculosis
may influence the biological variants of HIV that are expressed
in HIV-infected persons with active TB.
The association of CCR5 and CXCR4 with HIV infection
has been clearly demonstrated. Apart from their role as core-
ceptors for docking and subsequent viral entry into the host
cells, CCR5 and CXCR4 are also involved in HIV-1-induced
apoptosis.21 Thus, chemokine receptor expression is a critical
parameter for numerous processes. -Chemokines, which are
the natural ligands of HIV coreceptors, are thought to have a
dual role in HIV-1 infection. By binding to CCR5, they may
inhibit HIV-1 infection of target cells,22 but may also induce
HIV-1 replication by acting as mediators of inflammation, fa-
voring the accumulation of activated immune cells at the foci
of HIV replication, thereby exposing them to viral infection.23
This makes knowledge of HIV coreceptor expression and -
chemokine production during concurrent infection a clinically
important issue. The present study attempts to investigate
whether the presence of active tuberculosis infection induces
additional dysregulations in in vivo chemokine receptor ex-
pression and -chemokine production in HIV patients.
A number of studies have addressed the distribution and 
expression of CCR5 and CXCR4 on various immune cells of
HIV-1-infected persons,24–26 and it has been suggested that the
differential expression of these HIV-1 coreceptors has impor-
tant implications for HIV-1 tropism and pathogenesis in vivo.
HIV-1 isolates from individuals with early asymptomatic in-
fection are commonly nonsyncytium inducing (NSI) and utilize
CCR5 as the major coreceptor. In contrast, syncytium inducing
(SI) isolates are found in individuals with more advanced dis-
ease and are associated with an accelerated loss of CD4 lym-
phocytes and the acquisition of opportunistic infections.27–28
This switch in coreceptor usage has been well described for in-
dividuals infected with HIV-1 subtype B, but data from India,
Ethiopia, and Malawi have indicated that CXCR4-using iso-
lates are rarely found in individuals infected with HIV-1 sub-
type C, even at advanced stages of disease.29–32 Morris et al.33
reported that HIV-1 subtype C isolates from patients with ac-
tive tuberculosis used CCR5 as the major coreceptor for cellu-
lar entry. Since HIV-1 subtype C is the most rapidly spreading
viral subtype, accounting for more than 50% of incident infec-
tions worldwide, further analysis and monitoring of the pheno-
typic properties of HIV subtype C are therefore necessary and
justified. We therefore felt it necessary to determine the rela-
tive levels of CD4 cells expressing CCR5 and CXCR4, and
to measure circulating levels of -chemokines in individuals
living in an area where HIV-1 subtype C circulates and where
TB is endemic.
We observed that although there was no significant change
in CXCR4 expression on total T (CD3) cells based on disease
groupings, there was a significant decline in the fraction of
CD4 T cells expressing CXCR4 in HIV-infected individuals
as compared to those without HIV infection. Recently, a num-
ber of studies have shown downregulation of CXCR4 in HIV-
1 infected persons.25,34,35 Forster et al.25 found that CXCR4 ex-
pression on T cells in HIV-1-seropositive individuals was
equally down-regulated in both CD4 and CD8 T popula-
tions. Ostrowski et al.34 studied patients with other forms of
chronic immune activation, but did not detect a reduction in the
expression of CXCR4 on CD4 T cells, and therefore suggested
that the reduction in CXCR4 expression may be relatively spe-
cific to HIV-1 infection.
We also found reduced expression of CCR5 on total T cells
(CD3) in persons with TB, with HIV infection, and those with
both HIV and TB as compared to healthy controls. However,
analysis of the CD4 subset of T cells showed a significant de-
cline in CCR5 expression in HIV patients alone. Our results
contrast with those of Ostrowski et al.34 who demonstrated that
CCR5 expression was upregulated on CD4 T cells of HIV-1-
infected individuals when compared to uninfected controls. Yet
another group found the expression of CCR5 in HIV-1-infected
patients to be significantly increased on both CD4 and CD8
T cells.36 However, Shalekoff et al.35 in their study on
chemokine receptor expression in patients with HIV and TB
found that CCR5-expressing CD4 T cells were not elevated
in any of the disease groups. The variability in findings could
be related to differences in the genetic constitution of the pop-
ulations studied, the stage of disease, and the presence of other
opportunistic infections in the study subjects, since surface ex-
pression of CCR5 and CXCR4 among individuals is complex
and most likely regulated by multiple factors.
We observed that the presence of concomitant TB in HIV
patients did not result in significant changes in CCR5 and
CXCR4 expression on circulating CD3 and CD4 T cells. On
the other hand, Toossi et al.37 demonstrated increased expres-
sion of CCR5 on both CD4 T cells and macrophages in pleural
fluid from patients coinfected with HIV-1/TB. Fraziano et al.11
also found increased expression of CCR5 in human monocyte-
derived macrophages and alveolar macrophages in the course
of in vivo and in vitro M. tuberculosis infection. Further,
Rottman et al.38 reported evidence that an increased number of
CCR5-positive monocytes accumulate in the lungs of patients
in the course of active TB, and these sites of active M. tuber-
culosis infection in subjects coinfected with HIV-1/TB act as
epifoci of HIV replication and evolution, independent of sys-
temic HIV-1 activity. It could therefore be possible that
chemokine receptor expression at sites of M. tuberculosis in-
fection might be different from that observed systemically.
M. tuberculosis is known to induce synthesis and secretion
of numerous cytokines and chemokines that are potentially ca-
pable of modulating HIV-1 infection and/or replication.39,40 We
found that HIV patients with active TB had higher plasma lev-
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els of MIP-1 when compared to HIV-positive TB-negative pa-
tients as well as healthy controls. RANTES showed a pattern
similar to MIP-1. However, MIP-1 levels were elevated in
both HIV and TB patients when compared to healthy controls.
Though the increase in circulating MIP-1, MIP-1, and
RANTES levels in the HIV-positive TB group was not statis-
tically significant in comparison with the control group, we ob-
served a definite trend toward increased production of these
chemokines in HIV patients with active TB, indicating that HIV
and M. tuberculosis may have an additive effect on -
chemokine production. However, since asymptomatic HIV-pos-
itive controls were not included in this investigation, the rela-
tive contribution of infection with HIV and TB to chemokine
concentrations could not be obtained with certainty from our
measurements in HIV-seropositive TB patients.
The elevated -chemokine production in AIDS patients sug-
gests that these chemokines do not have a protective role against
disease progression either by their ability to competitively inhibit
HIV interaction with its coreceptor on CD4 T cells, or by a pro-
tective mechanism based on their chemotactic activities which
presumably regulate immune cells trafficking and inflammation.
Saha et al.41 demonstrated that CD4 clones from nonprogres-
sor patients and CD8 clones from AIDS patients secreted high
levels of RANTES, MIP-1, and MIP-1. In contrast, CD4
clones from AIDS patients produced no RANTES and little or
no MIP-1 or MIP-1. These results indicate that -chemokine
production by CD4 T cells but not CD8 T cells may consti-
tute one mechanism of disease-free survival for HIV-1-infected
individuals. Several recent studies have suggested that soluble
factors other than -chemokines, produced by CD8 T cells, can
play an important role in suppressing HIV-1 replication.42–46 It
is therefore also possible that in spite of the presence of elevated
levels of -chemokines, these individuals fail to produce suffi-
cient amounts of other HIV-1-suppressing factors, and thus fail
to prevent HIV-1 replication and disease progression.
In a recent prospective study of patients with HIV/TB coin-
fection, TB was found to exert its most significant effect on low-
ering survival rates in subjects with more preserved immuno-
logical status (that is, CD4 cell counts 200 cells/l).47 Since
the HIV-positive group in the present study was composed of
individuals with CD4 cell counts 200 cells/l, it could be pos-
sible that the effect of coinfection with M. tuberculosis could
not be clearly appreciated in these subjects. Therefore, it appears
that whereas at the site of M. tuberculosis infection, induction
of HIV-1 expression is demonstrable at all CD4 levels, the im-
pact of TB on HIV-1 systemically is most pronounced when pa-
tients have higher CD4 counts.
In conclusion, the dysregulations in -chemokine pathways
may affect the immunopathogenesis of HIV-1 differently in du-
ally infected patients, depending on the level of immunodefi-
ciency. Further analysis of the multifactorial interaction be-
tween HIV-1 and M. tuberculosis may lead to novel approaches
to effective drug and immune interventions.
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